Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RADNOR, Pa. , Dec. 16, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. ("Illumina") (NASDAQ: ILMN).

ILMN SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Illumina, Inc. (ILMN)

A U.S. appeals court on Friday struck down the U.S. Federal Trade Commission's order against Illumina's purchase of cancer diagnostic test maker Grail , a former subsidiary, saying the agency had applied the wrong legal standard in the antitrust case.

US court strikes down FTC order against Illumina's purchase of Grail

Illumina's market cap has fallen 80% from its all-time highs in 2021, but the divestment of Grail could bring it back on track. Illumina's competitive advantage lies in its scalable DNA sequencing platform and highly integrated system, which makes it difficult for customers to switch to competitors. The sale of Grail could unlock shareholder value, improve operating margins, and provide fresh liquidity for Illumina to invest in R&D and strengthen its core business.

Illumina: Grail's Divestment Could Unlock Significant Shareholder Value

Illumina Inc (NASDAQ:ILMN), a genetic testing company, accused European Union antitrust1B  regulators of overreach in their decision to stop its $7.1 billion acquisition of cancer detection test company Grail. In October, Illumina was ordered to sell Grail after closing its takeover of the cancer test maker before securing their approval.

Illumina's fight with EU regulators over $7.1B Grail acquisition rages on

Illumina said on Monday it had filed a registration statement with the U.S. securities regulator related to a potential divestiture of Grail , even as it challenges a European Union order to divest the cancer test maker in court.

Illumina files registration statement for potential Grail divestiture

SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has confidentially submitted a draft registration statement on Form 10 related to its potential divestiture of GRAIL to the U.S. Securities and Exchange Commission, pursuant to an order Illumina received from the European Commission (EC) directing the company to divest GRAIL. Submission of this registration statement is an important next step in evaluating divestiture options for GRAIL.

Illumina submits Form 10 to the Securities and Exchange Commission

The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.

Illumina (ILMN) Expands Globally Despite Macroeconomic Woes

NEW YORK , Dec. 8, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the "Class Period"), of the important January 9, 2024 lead plaintiff deadline. SO WHAT: If you purchased Illumina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ILMN

RADNOR, Pa. , Dec. 7, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. ("Illumina") (NASDAQ: ILMN).

ILMN CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Illumina, Inc. (ILMN)

Illumina remains by far the leader in the NGS sequencing market. After the divestment of Grail, Illumina's core business could become highly cash-generative again with close to 30% FCF margin to revenues. The stock suffered a perfect storm: end market slowdown, a highly cash-burning Grail and forced divestment, management removal, and the impact on FED rates. The worst seems to be behind.

Illumina: Conditions Are Met For A Rebound

If you suffered losses exceeding $100,000 investing in Illumina securities between May 1, 2023 and October 16, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ILMN.

ILLUMINA SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Illumina To Contact Him Directly To Discuss Their Options

LOS ANGELES, CA / ACCESSWIRE / December 4, 2023 /The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ: ILMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

GRAIL SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors in Illumina, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

GRAIL SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $ILMN #classactionlawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities during the period from May 1, 2023 through October 16, 2023 (the “Class Period”). Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. On August 10, 2023, Il.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Illumina, Inc. (ILMN) Investors and Encourages Investors to Contact the Firm Before January 9, 2024

If you purchased or acquired securities in Illumina between May 1, 2023 and October 16, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ILMN There is no cost or obligation to you.

ILLUMINA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Illumina To Contact Him Directly To Discuss Their Options

NEW YORK--(BUSINESS WIRE)---- $ILMN #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Illumina, Inc. (“Illumina” or “the Company”) (NASDAQ: ILMN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Illumina secur.

ILMN Shareholders Upcoming Deadline: Bronstein, Gewirtz & Grossman LLC Reminds Investors of The Illumina, Inc. to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Nov. 29, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the "Class Period"), of the important January 9, 2024 lead plaintiff deadline. SO WHAT: If you purchased Illumina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ILMN

Illumina, Inc. (NASDAQ:ILMN ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:30 AM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants David Westenberg - Piper Sandler David Westenberg All right. We're going to get started.

Illumina, Inc. (ILMN) Piper Sandler 35th Annual Healthcare Conference (Transcript)

ILMN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Illumina, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Illumina, Inc. (NASDAQ:ILMN ) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Joydeep Goswami - Chief Financial Officer Salli Schwartz - Vice President, Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar [Starts Abruptly] Everyone for joining us this morning. Pleasure to have with us Illumina.

Illumina, Inc. (ILMN) Evercore ISI 6th Annual HealthCONx Conference

RADNOR, Pa. , Nov. 28, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. ("Illumina") (NASDAQ: ILMN).

Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 1, 2023 and October 16, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 9, 2024.

GRAIL INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Illumina, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Nov. 27, 2023 /PRNewswire/ -- Attention Illumina, Inc. ("Illumina") (NASDAQ: ILMN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 1, 2023 and October 16, 2023. If you suffered a loss on your investment in Illumina, contact us about potential recovery by using the link below.

News for Illumina Stock (ILMN)